Besides, dysregulated expression of AACT and its glycan modification were also found in other types of diseases, including liver cancer, pancreatic cancer,[42] lung cancer,[43, 44] ovarian cancer,[45] sepsis and septic episode.[46] The mRNA expression level of AACT presented no obvious change for GC from the Gene Expression Profiling Interactive Analysis (GEPIA) database,[47] indicating that AACT‐N106‐H7N6S4F1 alterations in GC may attribute to the differences in protein or glycosylation levels. The gene discussed is SERPINA3; the disease is lung cancer.